Patent ID: 11919962
Assignee: BRISTOL-MYERS SQUIBB COMPANY
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of inhibiting IL-7 activity in a disease or condition in a subject in need thereof, the method comprising administering an effective amount of an isolated antibody or antigen-binding portion thereof to the subject, wherein said isolated antibody or antigen-binding portion thereof specifically binds to an alpha-chain of a human IL-7 receptor and comprises a heavy chain (HC) CDR1, CDR2, and CDR3, and a light chain (LC) CDR1, CDR2, and CDR3, and wherein:
(i) the heavy chain CDR1 comprises the amino acid sequence of SEQ ID NO: 13;
(ii) the heavy chain CDR2 comprises the amino acid sequence of SEQ ID NO: 14;
(iii) the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO: 15;
(iv) the light chain CDR1 comprises the amino acid sequence of SEQ ID NO: 16;
(v) the light chain CDR2 comprises the amino acid sequence of SEQ ID NO: 17; and
(vi) the light chain CDR3 comprises the amino acid sequence of SEQ ID NO: 18;
wherein said disease or condition is: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), ulcerative colitis (UC), systemic lupus erythematosus (SLE), lupus nephritis, multiple sclerosis (MS), atopic dermatitis, Sjogren's syndrome, asthma, type I diabetes, coronary artery disease, graft versus host disease, or autoimmune nephritis.